Research Article


DOI :10.26650/JARHS2024-1346413   IUP :10.26650/JARHS2024-1346413    Full Text (PDF)

THE EFFECT OF LINEZOLID AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCI BY VARIOUS METHODS

Başak Sıla EyüpGülseren Aktaş

Objectives: Enterococci are the causative agents of a variety of infections, particularly healthcare-associated infections. Linezolid is an important antibiotic in the treatment of infections caused by vancomycin-resistant enterococci. However, in recent years, an increasing rate of linezolid resistance has been reported in clinical enterococci strains. The aim of this study was to investigate the in vitro efficacy of linezolid against vancomycin-resistant Enterococcus (VRE) strains isolated from rectal swab samples of inpatients by disc diffusion, microdilution and E-test methods, and thus to evaluate the efficiency of linezolid against VRE strains by qualitative and quantitative methods.

Material and Methods: Fifty VRE strains were defined as enterococci by conventional methods. The efficiency of linezolid in strains was investigated by disk diffusion, E-test and microdilution methods. Species identification of enterococci strains was done with the GP24 Diagnostics kit.

Results: The identification of fifty enterococcal strains using the conventional methods revealed Gram-positive coccus, catalase-negative, bile growth-esculin hydrolysis positive, salt tolerance test (6.5% NaCl) positive, and L-pyrrolidonyl-β-naphthylamide (PYR) test positive. All strains were found to be susceptible to linezolid in disc diffusion, E-test and microdilution tests. In the microdilution test study, the MIC distrubution, MIC50 and MIC90 was detected as 1-2, 2 and 2 µg/mL, respectively. The MIC distribution, MIC50 and MIC90 values of linezolid by E-test were determined as 1-4, 2 and 3 µg/mL, respectively. In the study, 48 (96%) of 50 strains were identified as Enterococcus casseliflavus and 2 (4%) were Enterococcus faecium.

Conclusion: No linezolid resistance was detected in the study. This suggests that linezolid can be used safely in the treatment of VRE-induced infections. It will be important to conduct continuous and comprehensive studies on this subject and to monitor linezolid resistance surveillance.

DOI :10.26650/JARHS2024-1346413   IUP :10.26650/JARHS2024-1346413    Full Text (PDF)

LİNEZOLİDİN VANKOMİSİNE DİRENÇLİ ENTEROKOK SUŞLARINA ETKİSİNİN ÇEŞİTLİ YÖNTEMLERLE ARAŞTIRILMASI

Başak Sıla EyüpGülseren Aktaş

Amaç: Enterokoklar, özellikle sağlık hizmeti ile ilişkili enfeksiyonlar olmak üzere, çeşitli enfeksiyonların etkenidirler. Linezolid, vankomisine dirençli enterokokların sebep olduğu enfeksiyonların tedavisinde önemli bir antibiyotiktir. Fakat son yıllarda klinik enterokok suşlarında giderek artan oranlarda linezolid direnci rapor edilmektedir. Çalışmada, yatan hastaların rektal sürüntü örneklerinden izole edilen vankomisine dirençli enterokok (VRE) suşlarında linezolidin in vitro etkinliğinin disk difüzyon, E-test ve mikrodilüsyon yöntemleri ile araştırılması ve böylece linezolidin VRE suşlarına etkinliğinin kalitatif ve kantitatif yöntemler ile değerlendirilmesi amaçlanmıştır.

Gereç ve Yöntemler: Elli VRE suşu konvansiyonel yöntemler ile enterokok cinsi olarak tanımlanmıştır. Suşlarda, linezolidin etkinliği disk difüzyon, E-test ve mikrodilüsyon metodları ile araştırılmıştır. Enterokok suşlarının tür tanımlaması GP24 Diagnostics kiti ile yapılmıştır.

Bulgular: Elli enterokok suşunun konvansiyonel yöntemlerle tanımlanmasında Gram-pozitif kok, katalaz negatif, safrada üreme-eskülin hidrolizi pozitif, tuz tolerans testi (%6,5 NaCl) pozitif ve L-pirolidonil-βnaftilamid (PYR) testi pozitif olarak belirlenmiştir. Disk difüzyon, E-test ve mikrodilüsyon testleri ile suşların tümü, linezolide duyarlı bulunmuştur. Mikrodilüsyon test çalışmasında linezolid MİK dağılımı, MİK50 ve MİK90 değerleri sırasıyla 1-2, 2 ve 2 µg/mL olarak belirlenmiştir. Linezolidin E-test yöntemiyle yapılan MİK araştırması sonucunda MİK dağılımı, MİK50 ve MİK90 değerleri sırasıyla 1-4, 2 ve 3 µg/mL olarak saptanmıştır. Çalışmada 50 suştan 48’i (%96) Enterococcus casseliflavus ve 2 suş (%4) Enterococcus faecium olarak tanımlanmıştır.

Sonuç: Çalışmada linezolid direnci saptanmamıştır. Bu da linezolidin VRE kaynaklı enfeksiyonların tedavisinde güvenle kullanılabileceği fikrini vermektedir. Bu konuda devamlı ve kapsamlı çalışmaların yapılması ve linezolid direnç sürveyansının izlenmesi önemli olacaktır.


PDF View

References

  • Bender JK, Cattoir V, Hegstad K, Sadowy E, Coque TM, Westh H, et al. Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature. Drug Resist Updat 2018;40:25-39. google scholar
  • Murray PR, Rosental KS, Phaller MA, editors. Medical Microbiology. 8th ed. Philadelphia (PA): Elsevier Inc; 2016.p.183-201. google scholar
  • Brooks GF, Carroll KC, Butel JS, Morse SA, Mietzner TA, editors. Jawetz, Melnick & Adelberg’s Medical Microbiology. 25th ed. USA: The McGraw Hill Companies Inc; 2010.p.195-211. google scholar
  • Stogios PJ, Savchenko A. Molecular mechanisms of vancomycin resistance. Protein Sci 2020;29(3):654-69. google scholar
  • Liu BG, Yuan XL, He DD, Hu GZ, Miao MS, Xu EP. Research progress on the oxazolidinone drug linezolid resistance. Eur Rev Med Pharmacol Sci 2020;24(18):9274-81 google scholar
  • Turner AM, Lee JYH, Gorrie CL, Howden BP, Carter GP. Genomic insights into last-line antimicrobial resistance in multidrug-resistant Staphylococcus and vancomycin-resistant Enterococcus. Front Microbiol 2021;12:637656. google scholar
  • Procop GW, Church DL, Hall GS, Janda WM, Koneman EW, Schreckenberger PC, et al. Koneman’s Color Atlas and Textbook of Diagnostic Microbiology. 17th ed. Philadelphia: Wolters Kluwer Health; 2017.p.768-818. google scholar
  • Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: A CLSI supplement for global application. M100, 30th ed. Wayne, PA; 2020. google scholar
  • Turnidge JD, Bell JM. Antimicrobial susceptibility on solid media. In: Lorian V, editor. Antibiotics in laboratory medicine.Philadelphia: Wolters Kluwer Health; 2017.p.768-818 google scholar
  • Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. CLSI document M07-A9. 9th ed. Wayne, PA; 2012. https://www.researchgate.net/file. PostFileLoader.html?id=564ceedf5e9d97daf08b45a2&assetKey =AS%3A297254750572544%401447882463055 google scholar
  • World Health Organization. Report on the burden of endemic health care-associated infection worldwide. 12.07.2011. https:// www.who.int/publications/i/item/report-on-the-burden-of-endemic-health-care-associated-infection-worldwide. google scholar
  • Toney-Butler TJ, Gasner A, Carver N. Hand Hygiene. In: StatPearls. Treasure Island (FL). StatPearls Publishing; 2023. https://www. ncbi.nlm.nih.gov/books/NBK470254/ google scholar
  • Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. Department of Health and Human Services (US). CDC; 2019. https://www.cdc.gov/drugresistance/ biggest-threats.html google scholar
  • Monticelli J, Knezevich A, Luzzati R, Di Bella S. Clinical management of non-faecium non-faecalis vancomycin-resistant enterococci infection. Focus on Enterococcus gallinarum and Enterococcus casseliflavus/flavescens. J Infect Chemother 2018;24(4):237-46. google scholar
  • Schouten MA, Voss A, Hoogkamp-Korstanje JA. Antimicrobial susceptibility patterns of enterococci causing infections in Europe. The European VRE Study Group. Antimicrob Agents Chemother 1999;43(10):2542-6. google scholar
  • Alçi G, Güneşer D, Güner A, Karahasan A. Hastanede yatan hastalardan alınan rektal sürüntü örneklerinde vankomisine dirençli enterokok taranması: Stratejik değerlendirme. ANKEM Derg 2021;35(3):70-6. google scholar
  • Olearo F, Both A, Belmar CC, Hilgarth H, Klupp EM, Hansen JL, et al. Emergence of linezolid-resistance in vancomycin-resistant Enterococcus faecium ST117 associated with increased linezolid-consumption. Int J Med Microbiol 2021;311(2):151477. google scholar
  • Klare I, Fleige C, Geringer U, Thürmer A, Bender J, Mutters NT, et al. Increased frequency of linezolid resistance among clinical Enterococcus faecium isolates from German hospital patients. J Glob Antimicrob Resist 2015;3(2):128-31. google scholar
  • Baysallar M, Kilic A, Aydogan H, Cilli F, Doganci L. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey. Int j Antimicrob Agents 2004;23(5):510-2. google scholar
  • Aktaş G, Bozdoğan B, Derbentli S. Linezolid ve dalbavansinin vankomisine dirençli enterokok suşlarına karşı in vitro aktivitesi [In vitro activity of linezolid and dalbavancin against vancomycin-resistant enterococci]. Mikrobiyol Bul 2012;46(3):359-65. google scholar
  • Öcal D, Gürbüz OA, Dansuk Z, Kuzucu EA, Altunay E, Apaydın N, et al. Kan kültürlerinden izole edilen Enterococcus faecium ve Enterococcus faecalis suşlarının in-vitro daptomisin ve linezolid duyarlılık profilleri Türk Mikrobiyol Cem Derg 2017;47(3):125-30. google scholar
  • Çomoğlu Ş, Kaya Ş, Ceran N, Aksöz S, Öztürk S, Karagöz G. Determination of in vitro activity of linezolid in resistance Gram-positive bacteria by E-Test method. Haydarpasa Numune Med J 2019;59(1):25-30. google scholar
  • Maschieto A, Martinez R, Palazzo ICV, Darini ALDC. Antimicrobial resistance of Enterococcus sp. isolated from the intestinal tract of patients from a university hospital in Brazil. Mem Inst Oswaldo Cruz 2004;99(7):763-7. google scholar
  • Perio M, Yarnold P, Warren J, Noskin G. Risk factors and outcomes associated with non-Enterococcus faecalis, non-Enterococcus faecium enterococcal bacteremia. Infect Control Hosp Epidemiol, 2006;27(1):28-33. google scholar
  • Yasliani S, Mohabati MA, Hosseini DR, Satari M, Teymornejad O. Linezolid vancomycin resistant Enterococcus isolated from clinical samples in Tehran hospitals. Indian J Med Sci 2009;63(7):297-302. google scholar
  • Suzuki H, Hase R, Otsuka Y, Hosokawa N. A 10-year profile of enterococcal bloodstream infections at a tertiary-care hospital in Japan. J Infect Chemother 2017;23(6):390-3. google scholar
  • Tan CK, Lai CC, Wang JY, Lin SH, Liao CH, Huang YT, et al. Bacteremia caused by non-faecalis and non-faecium enterococcus species at a medical center in Taiwan, 2000 to 2008. J Infect 2010;61(1):34-43. google scholar
  • Britt NS, Potter EM. Clinical epidemiology of vancomycin-resistant Enterococcus gallinarum and Enterococcus casseliflavus bloodstream infections. J Glob Antimicrob Resist 2016;5:57-61. google scholar
  • Sengupta M, Sarkar R, Sarkar S, Sengupta M, Ghosh S, Banerjee P. Vancomycin and linezolid-resistant Enterococcus isolates from a tertiary care center in India. Diagnostics (Basel) 2023;13(5):945. google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Eyüp, B.S., & Aktaş, G. (2024). THE EFFECT OF LINEZOLID AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCI BY VARIOUS METHODS. Journal of Advanced Research in Health Sciences, 7(1), 37-42. https://doi.org/10.26650/JARHS2024-1346413


AMA

Eyüp B S, Aktaş G. THE EFFECT OF LINEZOLID AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCI BY VARIOUS METHODS. Journal of Advanced Research in Health Sciences. 2024;7(1):37-42. https://doi.org/10.26650/JARHS2024-1346413


ABNT

Eyüp, B.S.; Aktaş, G. THE EFFECT OF LINEZOLID AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCI BY VARIOUS METHODS. Journal of Advanced Research in Health Sciences, [Publisher Location], v. 7, n. 1, p. 37-42, 2024.


Chicago: Author-Date Style

Eyüp, Başak Sıla, and Gülseren Aktaş. 2024. “THE EFFECT OF LINEZOLID AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCI BY VARIOUS METHODS.” Journal of Advanced Research in Health Sciences 7, no. 1: 37-42. https://doi.org/10.26650/JARHS2024-1346413


Chicago: Humanities Style

Eyüp, Başak Sıla, and Gülseren Aktaş. THE EFFECT OF LINEZOLID AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCI BY VARIOUS METHODS.” Journal of Advanced Research in Health Sciences 7, no. 1 (May. 2024): 37-42. https://doi.org/10.26650/JARHS2024-1346413


Harvard: Australian Style

Eyüp, BS & Aktaş, G 2024, 'THE EFFECT OF LINEZOLID AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCI BY VARIOUS METHODS', Journal of Advanced Research in Health Sciences, vol. 7, no. 1, pp. 37-42, viewed 2 May. 2024, https://doi.org/10.26650/JARHS2024-1346413


Harvard: Author-Date Style

Eyüp, B.S. and Aktaş, G. (2024) ‘THE EFFECT OF LINEZOLID AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCI BY VARIOUS METHODS’, Journal of Advanced Research in Health Sciences, 7(1), pp. 37-42. https://doi.org/10.26650/JARHS2024-1346413 (2 May. 2024).


MLA

Eyüp, Başak Sıla, and Gülseren Aktaş. THE EFFECT OF LINEZOLID AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCI BY VARIOUS METHODS.” Journal of Advanced Research in Health Sciences, vol. 7, no. 1, 2024, pp. 37-42. [Database Container], https://doi.org/10.26650/JARHS2024-1346413


Vancouver

Eyüp BS, Aktaş G. THE EFFECT OF LINEZOLID AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCI BY VARIOUS METHODS. Journal of Advanced Research in Health Sciences [Internet]. 2 May. 2024 [cited 2 May. 2024];7(1):37-42. Available from: https://doi.org/10.26650/JARHS2024-1346413 doi: 10.26650/JARHS2024-1346413


ISNAD

Eyüp, BaşakSıla - Aktaş, Gülseren. THE EFFECT OF LINEZOLID AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCI BY VARIOUS METHODS”. Journal of Advanced Research in Health Sciences 7/1 (May. 2024): 37-42. https://doi.org/10.26650/JARHS2024-1346413



TIMELINE


Submitted19.08.2023
Accepted08.11.2023
Published Online06.02.2024

LICENCE


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


SHARE




Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.